Atezolizumab is approved by FDA as adjuvant treatment for non-small cell lung cancer

Share This Post

Nov 2021: The Food and Drug Administration has approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumours contain PD-L1 expression on less than 1% of tumour cells, as assessed by an FDA-approved test.

The VENTANA PD-L1 (SP263) Assay (Ventana Medical Systems, Inc.) was also authorised by the FDA today as a companion diagnostic device for selecting patients with NSCLC for adjuvant treatment with Tecentriq.

Disease-free survival (DFS) was the key efficacy outcome measure, as determined by the investigator in the primary efficacy analysis population (n=476) of patients with stage II-IIIA NSCLC with PD-L1 expression on 1% of tumour cells (PD-L1 1% TC). In the atezolizumab arm, median DFS was not reached (95 percent CI: 36.1, NE) compared to 35.3 months (95 percent CI: 29.0, NE) in the BSC arm (HR 0.66; 95 percent CI: 0.50, 0.88; p=0.004).

The DFS HR was 0.43 in a pre-specified secondary subgroup analysis of patients with PD-L1 TC 50% stage II-IIIA NSCLC (95 percent CI: 0.27, 0.68). The DFS HR was 0.87 in an exploratory subgroup study of patients with PD-L1 TC 1-49 percent stage II-IIIA NSCLC (95 percent CI: 0.60, 1.26).

Increased aspartate aminotransferase, blood creatinine, and alanine aminotransferase, as well as hyperkalemia, rash, cough, hypothyroidism, pyrexia, fatigue/asthenia, musculoskeletal pain, peripheral neuropathy, arthralgia, and pruritus, were the most common (ten percent) adverse reactions in patients receiving atezolizumab, including laboratory abnormalities.

For this indication, the recommended atezolizumab dose is 840 mg every two weeks, 1200 mg every three weeks, or 1680 mg every four weeks for up to a year.

Take second opinion on lung cancer treatment

Send Details

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

How Targeted Therapy is Revolutionizing Advanced Cancer Treatment

How Targeted Therapy is Revolutionizing Advanced Cancer Treatment?

In the field of oncology, the emergence of targeted therapy has revolutionized the treatment landscape for advanced cancers. Unlike conventional chemotherapy, which broadly targets rapidly dividing cells, targeted therapy aims to selectively attack cancer cells while minimizing damage to normal cells. This precision approach is made possible by identifying specific molecular alterations or biomarkers that are unique to cancer cells. By understanding the molecular profiles of tumors, oncologists can tailor treatment regimens that are more effective and less toxic. In this article, we delve into the principles, applications, and advancements of targeted therapy in advanced cancer.

Utilizing Immunotherapy to Treat Late-Stage Cancers

Utilizing Immunotherapy to Treat Late-Stage Cancers

  Introduction Immunotherapy has become a groundbreaking method in cancer treatment, especially for advanced-stage cancer treatments that have demonstrated minimal effectiveness with standard medicines. This

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy